Sure, the biopharmaceutical giant in the Fortune 200 is Amgen.
Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. It is one of the largest biotech companies in the world, with a market capitalization of over $200 billion. Amgen develops, manufactures, and markets bio medicines for the treatment of cancer, kidney disease, rheumatoid arthritis, and other chronic diseases.
Amgen was founded in 1980 by George B. Rathmann and other scientists who had worked on the development of the first biotechnology product, Humulin, a human insulin. The company went public in 1983 and has since grown to become a global leader in the development of bio medicines.
Amgen is a Fortune 200 company and is ranked #38 on the 2023 Fortune 500 list. It is also the world's largest biotech company by revenue. Amgen employs over 29,000 people worldwide and has research and development facilities in the United States, Europe, and Asia.
In 2022, Amgen generated $30.2 billion in revenue and $14.2 billion in net income. The company's most popular products include Enbrel, Neulasta, and Prolia.
Post a Comment
Post a Comment